Skip to main content
. 2024 Mar 4;9(11):12478–12499. doi: 10.1021/acsomega.3c09339

Figure 7.

Figure 7

The key binding sites of TAO with inhibitors. (A) The binding hydrophobic cavity of TAO with colletochlorin B. (B) Structure and activities of colletochlorin B. (C) The binding site of TAO with colletochlorin B. (D) The two binding sites mentioned in (G) and (H). (E) The binding site of TAO with compound 17. (F) Structure and activities of compound 17. (G) The binding site of TAO with compound 17b. (H) Structure and activities of compound 17b. (I) The binding site of TAO with ferulenol. (J) Structure and activities of ferulenol. (K) The conserved binding site of TAO. These figures of crystal structures were drawn with PyMol, and the AOX model used is TAO (A,C,D,K, PDB: 3W54; E, PDB: 5GN7; G, PDB: 5GN9; I, PDB: 5ZDP).